Claims for Patent: 12,214,010

Summary for Patent: 12,214,010

Title:	Desmopressin oral compositions
Abstract:	Provided herein are desmopressin oral liquid formulations. Also provided herein are methods of making and using desmopressin oral liquid compositions for the treatment of certain diseases including diabetes insipidus, enuresis, hemophilia A, von willebrand disease, high blood urea levels and others.
Inventor(s):	Yu-Hsing Tu, Kalyan Kathala, Romona BHATTACHARYA, Yingjun Fan, Ashok Perumal
Assignee:	Tulex Pharmaceuticals Inc
Application Number:	US18/625,923
Patent Claims:	1. A liquid pharmaceutical composition comprising a) desmopressin acetate, wherein desmopressin acetate is present in an amount of from about 0.01 mg/mL to about 0.1 mg/mL; b) a two-component, dual-functional, preservative-buffer system that comprises sodium benzoate and benzoic acid, wherein the two-component, dual-functional, preservative-buffer system provides a pH of the liquid pharmaceutical composition that is about 5.0; and c) water; wherein the liquid pharmaceutical composition is an oral solution. 2. The liquid pharmaceutical composition of claim 1, wherein desmopressin acetate is present in an amount from of about 0.03 mg/mL to about 0.07 mg/mL. 3. The liquid pharmaceutical composition of claim 1, wherein desmopressin acetate is present in an amount of about 0.05 mg/mL. 4. The liquid pharmaceutical composition of claim 1, wherein benzoic acid is present in an amount of from about 0.005% w/v to about 0.1% w/v. 5. The liquid pharmaceutical composition of claim 1, wherein benzoic acid is present in an amount of from about 0.02% w/v to about 0.05% w/v. 6. The liquid pharmaceutical composition of claim 1, wherein sodium benzoate is present in an amount of from about 0.01% w/v to about 0.6% w/v. 7. The liquid pharmaceutical composition of claim 1, wherein sodium benzoate is present in an amount of from about 0.15% w/v to about 0.32% w/v. 8. The liquid pharmaceutical composition of claim 1, wherein benzoic acid and sodium benzoate are present in an amount of from about 0.25% w/v to about 0.35% w/v. 9. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition further comprises a preservative, and wherein the preservative comprises an antimicrobial agent, a chelating agent, an antioxidant, or a combination thereof. 10. The liquid pharmaceutical composition of claim 9, wherein the preservative comprises a paraben or mixture of parabens. 11. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition has a pH that is about 5.0 after stored at 40° C.±2° C. and 75±5% RH for at least 6 months. 12. The liquid pharmaceutical composition of claim 1, comprising: a) desmopressin acetate in an amount of from about 0.01 mg/mL to about 0.1 mg/mL; b) sodium benzoate in an amount of from about 0.18% w/v to about 0.4% w/v; c) benzoic acid in an amount of from about 0.02% w/v to about 0.1% w/v; and d) water. 13. The liquid pharmaceutical composition of claim 1, comprising: a) desmopressin acetate in an amount of from about 0.025 mg/mL to about 0.075 mg/mL; b) sodium benzoate in an amount of from about 0.2% w/v to about 0.35% w/v; c) benzoic acid in an amount of from about 0.03% w/v to about 0.04% w/v; and d) water. 14. The liquid pharmaceutical composition of claim 1, comprising: a) desmopressin acetate in an amount of about 0.05 mg/mL; b) sodium benzoate in an amount of about 0.285% w/v; c) benzoic acid in an amount of about 0.034% w/v; and d) water. 15. The liquid pharmaceutical composition of claim 1, consisting essentially of: a) desmopressin acetate in an amount of about 0.05 mg/ml; b) sodium benzoate in an amount of about 0.285% w/v; c) benzoic acid in an amount of about 0.034% w/v; and d) water. 16. The liquid pharmaceutical composition of claim 1, consisting of a) desmopressin acetate in an amount of about 0.05 mg/mL; b) sodium benzoate in an amount of about 0.285% w/v; c) benzoic acid in an amount of about 0.034% w/v; and d) water. 17. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition is ready-to-use without dilution or addition of any further components to the liquid pharmaceutical composition. 18. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition contains no more than 5% wt of total impurities and not more than 1% wt of each of the following impurities: [Asp5] desmopressin, [Glu4] desmopressin, [Gly′OH] desmopressin, [L-Arg8] desmopressin, [Gln4 (Acm)] desmopressin, [Asn5 (Acm)] desmopressin, and [Gly9N (CH3)2] desmopressin after stored at 40° C.±2° C. and 75±5% RH humidity for 6 months, wherein the amount of impurities is determined according to High-performance liquid chromatography (HPLC) method. 19. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition retains at least 90% wt of the initial desmopressin acetate amount after stored at 40° C.±2° C. and 75±5% RH for 6 months, wherein the desmopressin acetate amount is determined according to High-performance liquid chromatography (HPLC) method. 20. The liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition exhibits a bioavailability that is bioequivalent to a reference oral tablet composition comprising desmopressin acetate, when measured as the total area under the curve (AUC) after oral administration or when measured as Cmax after oral administration. 21. A direct dosing device comprising the liquid pharmaceutical composition of claim 1. 22. A kit comprising a package enclosing the liquid pharmaceutical composition of claim 1.